Diabetes mellitus (DM) is a metabolic disease, which arises from a complete deficiency of insulin production or inability to utilize this hormone. Potential antibodies, genes associated with diabetes have the potential to be therapeutic targets for diabetes. As an experienced drug discovery company, Ace Therapeutics can provide the therapy and drug discovery services related to diabetes.

Therapies of Diabetes

Diabetes mellitus is a serious and lifelong condition commonly characterized by abnormally elevated blood glucose levels due to a failure in insulin production or a decrease in insulin sensitivity and function. If left untreated, diabetes can cause many health complications. Acute complications can include diabetic ketoacidosis, hyperosmolar hyperglycemic state, or death. Besides insulin and oral hypoglycemic agents, other treatments such as gene therapy and induced β-cells regeneration can be introduced to manage diabetes.

• Small Molecule Drug
  Insulin injection remains the main treatment for T1DM. Exogenous insulin can be combined with various oral antidiabetic drugs to allow insulin dosage lowering for T2DM.



• Antibody Therapy
  Diabetes is widely considered to be a T cell driven autoimmune disease resulting in reduced insulin production due to dysfunction/destruction of pancreatic β-cells. there continues to be a need for immunotherapies that selectively reestablish persistent β cell-specific self-tolerance for the prevention and remission of diabetes. The utilization of monoclonal antibodies (mAb) is one strategy to target specific immune cell populations inducing autoimmune-driven pathology.

mAb therapies to ameliorate type 1 diabetes (Ke, Qi et al. 2021)

Our Services

The compound has the desired activity in a compound screen and whose activity is confirmed upon retesting. Ace Therapeutics can provide a complementary set of technologies to help with the drugs discovery. Our services include but not limited to the followings.

Features of Our Services

Ace Therapeutics can accelerate the therapeutic development and drug discovery process about diabetes for our clients worldwide. Our assays are developed and processed with the highest standard and the results are delivered on time without compromising quality. Most of those assays are suitable for drug discovery. Please feel free to contact us.

References

1. Donath, M. Y. Targeting inflammation in the treatment of type 2 diabetes: time to start. Nature Reviews Drug Discovery, 2014, 13(6), 465–476.
2. Ke, Qi et al. "Evolving Antibody Therapies for the Treatment of Type 1 Diabetes." Frontiers in immunology vol. 11 624568. 18 Feb. 2021

• Target Identification Service
• Lead Optimization Service
• Preclinical Development Service

• Mouse Models
• Assay Kits
• Antibodies
• Cell Lines & Lysates
• Proteins & Peptides
• Inhibitors & Activators